

Accepted Manuscript

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab


Konstantinos Papamichael, Karen A. Chachu, Ravy Vajravelu, Byron P. Vaughn, Josephine Ni, Mark T. Osterman, Adam S. Cheifetz

PII: S1542-3565(17)30385-3
DOI: [10.1016/j.cgh.2017.03.031](https://doi.org/10.1016/j.cgh.2017.03.031)
Reference: YJCGH 55175

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 21 March 2017

Please cite this article as: Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Osterman MT, Cheifetz AS, Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab, *Clinical Gastroenterology and Hepatology* (2017), doi: 10.1016/j.cgh.2017.03.031.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving**
2 **Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab**

3 Konstantinos Papamichael¹, Karen A. Chachu², Ravy Vajravelu³, Byron P. Vaughn⁴, Josephine
4 Ni³, Mark T. Osterman^{3*} Adam S. Cheifetz^{1*}

5 *equal contribution

6 ¹Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess
7 Medical Center, Harvard Medical School, Boston, Massachusetts.

8 ²Department of Medicine, Division of Gastroenterology, Duke University School of Medicine,
9 Durham, North Carolina.

10 ³Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
11 Philadelphia, Pennsylvania.

12 ⁴Department of Gastroenterology, Hepatology and Nutrition, University of Minnesota,
13 Minneapolis, MN, USA.

14

15 **Corresponding author:**

16 Adam S. Cheifetz, MD

17

18 Director, Center for Inflammatory Bowel Disease
19 Beth Israel Deaconess Medical Center
20 330 Brookline Ave., Rabb 425, Boston, MA 02215
21 Associate Professor of Medicine, Harvard Medical School
22 e-mail: acheifet@bidmc.harvard.edu
23 Phone: (617) 667-2802, Fax: (617) 667-5826

24

25 **Short title:** Infliximab therapeutic drug monitoring in IBD

26

Download English Version:

<https://daneshyari.com/en/article/5657292>

Download Persian Version:

<https://daneshyari.com/article/5657292>

[Daneshyari.com](https://daneshyari.com)